SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus
Abstract
:1. Introduction
2. Material and Methods
2.1. Study Group
2.2. SARS-CoV-2 Microneutralization Assay
2.3. SARS-CoV-2 Antibody Immunoassays
2.4. Statistical Analysis
3. Results
3.1. Neutralizing Antibodies in Symptomatic COVID-19 Patients Are Detected Early upon Infection and May Persist Over 11 Months
3.2. Orienting the Choice of the Serological Platform to Assess Ab-Mediated Protection
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
INMI COVID-19 Laboratory Team
Conflicts of Interest
References
- Boodman, C.; Lagacé-Wiens, P.; Bullard, J. Diagnostic testing for SARS-CoV-2. CMAJ 2020, 192, E713. [Google Scholar] [CrossRef]
- Barnes, C.O.; West, A.P.; Huey-Tubman, K.E.; Hoffmann, M.A.G.; Sharaf, N.G.; Hoffman, P.R.; Koranda, N.; Gristick, H.B.; Gaebler, C.; Muecksch, F.; et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell 2020, 182, 828–842.e16. [Google Scholar] [CrossRef] [PubMed]
- Focosi, D.; Maggi, F.; Mazzetti, P.; Pistello, M. Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy. Rev. Med. Virol. 2020, 31, e2170. [Google Scholar] [PubMed]
- The ARDS Definition Task Force Acute Respiratory Distress Syndrome. JAMA 2012, 307, 2526–2533.
- EVA. EVAg Portal. Available online: https://www.european-virus-archive.com/virus/sars-cov-2-isolate-sars-cov-2humanitapavia107342020-clade-g-d614g-s (accessed on 8 March 2021).
- Garcia-Beltran, W.F.; Lam, E.C.; Astudillo, M.G.; Yang, D.; Miller, T.E.; Feldman, J.; Hauser, B.M.; Caradonna, T.M.; Clayton, K.L.; Nitido, A.D.; et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 2021, 184, 476–488.e11. [Google Scholar] [CrossRef]
- Rydyznski Moderbacher, C.; Ramirez, S.I.; Dan, J.M.; Grifoni, A.; Hastie, K.M.; Weiskopf, D.; Belanger, S.; Abbott, R.K.; Kim, C.; Choi, J.; et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 2020, 183, 996–1012.e19. [Google Scholar] [CrossRef] [PubMed]
- Wu, F.; Liu, M.; Wang, A.; Lu, L.; Wang, Q.; Gu, C.; Chen, J.; Wu, Y.; Xia, S.; Ling, Y.; et al. Evaluating the Association of Clinical Characteristics with Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern. Med. 2020, 180, 1356. [Google Scholar] [CrossRef]
- Kalkan Yazıcı, M.; Koç, M.M.; Çetin, N.S.; Karaaslan, E.; Okay, G.; Durdu, B.; Sümbül, B.; Doymaz, M.Z. Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19. J. Immunol. 2020, 205, 2719–2725. [Google Scholar] [CrossRef]
- Trinité, B.; Tarrés-Freixas, F.; Rodon, J.; Pradenas, E.; Urrea, V.; Marfil, S.; Rodríguez de la Concepción, M.L.; Ávila-Nieto, C.; Aguilar-Gurrieri, C.; Barajas, A.; et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci. Rep. 2021, 11, 2608. [Google Scholar] [CrossRef]
- Boonyaratanakornkit, J.; Morishima, C.; Selke, S.; Zamora, D.; McGuffin, S.; Shapiro, A.E.; Campbell, V.L.; McClurkan, C.L.; Jing, L.; Gross, R.; et al. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. J. Clin. Investig. 2021, 131, e144930. [Google Scholar] [CrossRef]
- Wang, X.; Guo, X.; Xin, Q.; Pan, Y.; Hu, Y.; Li, J.; Chu, Y.; Feng, Y.; Wang, Q. Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. Clin. Infect. Dis. 2020, 71, 2688–2694. [Google Scholar] [CrossRef] [PubMed]
- Seow, J.; Graham, C.; Merrick, B.; Acors, S.; Pickering, S.; Steel, K.J.A.; Hemmings, O.; O’Byrne, A.; Kouphou, N.; Galao, R.P.; et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 2020, 5, 1598–1607. [Google Scholar] [CrossRef] [PubMed]
- Agenzia Italiana del Farmaco e Istituto Superiore di Sanità. Transfusion of Convalescent Plasma for the Early Treatment of Pneumonia due to SARS-CoV2 (TSUNAMI Study): A Multicenter Open Label Randomized Control Trial; Ministero della Salute: Rome, Italy, 2020.
- Gambardella, C.; Pagliuca, R.; Pomilla, G.; Gambardella, A. COVID-19 risk contagion: Organization and procedures in a South Italy geriatric oncology ward. J. Geriatr. Oncol. 2020, 11, 1187–1188. [Google Scholar] [CrossRef] [PubMed]
- Tolone, S.; Gambardella, C.; Brusciano, L.; del Genio, G.; Lucido, F.S.; Docimo, L. Telephonic triage before surgical ward admission and telemedicine during COVID-19 outbreak in Italy. Effective and easy procedures to reduce in-hospital positivity. Int. J. Surg. 2020, 78, 123–125. [Google Scholar] [CrossRef] [PubMed]
- Chia, W.N.; Zhu, F.; Ong, S.W.X.; Young, B.E.; Fong, S.-W.; Le Bert, N.; Tan, C.W.; Tiu, C.; Zhang, J.; Tan, S.Y.; et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: A longitudinal study. Lancet Microbe 2021. Epub ahead of print. [Google Scholar] [CrossRef]
- Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Yu, E.D.; Faliti, C.E.; Grifoni, A.; Ramirez, S.I.; Haupt, S.; Frazier, A.; et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021, 371, eabf4063. [Google Scholar] [CrossRef]
- Cunha, L.L.; Perazzio, S.F.; Azzi, J.; Cravedi, P.; Riella, L.V. Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response. Front. Immunol. 2020, 11, 1748. [Google Scholar] [CrossRef] [PubMed]
- Taefehshokr, N.; Taefehshokr, S.; Heit, B. Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. Pathogens 2020, 9, 1027. [Google Scholar] [CrossRef] [PubMed]
- Choe, P.G.; Kang, C.K.; Suh, H.J.; Jung, J.; Song, K.-H.; Bang, J.H.; Kim, E.S.; Kim, H.B.; Park, S.W.; Kim, N.J.; et al. Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection. Emerg. Infect. Dis. 2021, 27, 327. [Google Scholar] [CrossRef]
- Hartley, G.E.; Edwards, E.S.J.; Aui, P.M.; Varese, N.; Stojanovic, S.; McMahon, J.; Peleg, A.Y.; Boo, I.; Drummer, H.E.; Hogarth, P.M.; et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci. Immunol. 2020, 5, eabf8891. [Google Scholar] [CrossRef]
- Marot, S.; Malet, I.; Leducq, V.; Zafilaza, K.; Sterlin, D.; Planas, D.; Gothland, A.; Jary, A.; Dorgham, K.; Bruel, T.; et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat. Commun. 2021, 12, 844. [Google Scholar] [CrossRef]
- Milani, G.P.; Dioni, L.; Favero, C.; Cantone, L.; Macchi, C.; Delbue, S.; Bonzini, M.; Montomoli, E.; Bollati, V. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci. Rep. 2020, 10, 20048. [Google Scholar] [CrossRef] [PubMed]
- Sterlin, D.; Mathian, A.; Miyara, M.; Mohr, A.; Anna, F.; Claër, L.; Quentric, P.; Fadlallah, J.; Devilliers, H.; Ghillani, P.; et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 2021, 13, eabd2223. [Google Scholar] [CrossRef]
- Varnaitė, R.; García, M.; Glans, H.; Maleki, K.T.; Sandberg, J.T.; Tynell, J.; Christ, W.; Lagerqvist, N.; Asgeirsson, H.; Ljunggren, H.-G.; et al. Expansion of SARS-CoV-2–Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. J. Immunol. 2020, 205, 2437–2446. [Google Scholar] [CrossRef] [PubMed]
- Mazzini, L.; Martinuzzi, D.; Hyseni, I.; Benincasa, L.; Molesti, E.; Casa, E.; Lapini, G.; Piu, P.; Trombetta, C.M.; Marchi, S.; et al. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J. Immunol. Methods 2021, 489, 112937. [Google Scholar] [CrossRef] [PubMed]
- Klingler, J.; Weiss, S.; Itri, V.; Liu, X.; Oguntuyo, K.Y.; Stevens, C.; Ikegame, S.; Hung, C.-T.; Enyindah-Asonye, G.; Amanat, F.; et al. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. J. Infect. Dis. 2020, 223, 957–970. [Google Scholar]
- Rosado, J.; Pelleau, S.; Cockram, C.; Merkling, S.H.; Nekkab, N.; Demeret, C.; Meola, A.; Kerneis, S.; Terrier, B.; Fafi-Kremer, S.; et al. Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: An antibody-based diagnostic and machine learning study. Lancet Microbe 2021, 2, e60–e69. [Google Scholar] [CrossRef]
- Taylor, S.C.; Hurst, B.; Charlton, C.L.; Bailey, A.; Kanji, J.N.; McCarthy, M.K.; Morrison, T.E.; Huey, L.; Annen, K.; DomBourian, M.G.; et al. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. J. Clin. Microbiol. 2021, 59, e02438-20. [Google Scholar] [CrossRef]
- Muruato, A.E.; Fontes-Garfias, C.R.; Ren, P.; Garcia-Blanco, M.A.; Menachery, V.D.; Xie, X.; Shi, P.-Y. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 2020, 11, 4059. [Google Scholar] [CrossRef] [PubMed]
- Tan, C.W.; Chia, W.N.; Qin, X.; Liu, P.; Chen, M.I.-C.; Tiu, C.; Hu, Z.; Chen, V.C.-W.; Young, B.E.; Sia, W.R.; et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat. Biotechnol. 2020, 38, 1073–1078. [Google Scholar] [CrossRef]
- Byrnes, J.R.; Zhou, X.X.; Lui, I.; Elledge, S.K.; Glasgow, J.E.; Lim, S.A.; Loudermilk, R.P.; Chiu, C.Y.; Wang, T.T.; Wilson, M.R.; et al. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. mSphere 2020, 5, e00802-20. [Google Scholar] [CrossRef] [PubMed]
- Chi, X.; Yan, R.; Zhang, J.; Zhang, G.; Zhang, Y.; Hao, M.; Zhang, Z.; Fan, P.; Dong, Y.; Yang, Y.; et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 2020, 369, 650–655. [Google Scholar] [CrossRef] [PubMed]
- Yoshida, S.; Ono, C.; Hayashi, H.; Fukumoto, S.; Shiraishi, S.; Tomono, K.; Arase, H.; Matsuura, Y.; Nakagami, H. SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals. Sci. Rep. 2021, 11, 5934. [Google Scholar] [CrossRef] [PubMed]
- McCallum, M.; De Marco, A.; Lempp, F.A.; Tortorici, M.A.; Pinto, D.; Walls, A.C.; Beltramello, M.; Chen, A.; Liu, Z.; Zatta, F.; et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 2021, in press. [Google Scholar] [CrossRef]
- Suryadevara, N.; Shrihari, S.; Gilchuk, P.; VanBlargan, L.A.; Binshtein, E.; Zost, S.J.; Nargi, R.S.; Sutton, R.E.; Winkler, E.S.; Chen, E.C.; et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 2021, in press. [Google Scholar] [CrossRef] [PubMed]
Anti-S IgG AU/mL | ≥1:160/Total | % ≥1:160 | % Donor Lost | Spared NAb Tests |
---|---|---|---|---|
0–400 | 105/402 | 26.10 | 0.00 | 0 |
15–400 | 105/391 | 26.80 | 0.00 | 11 |
60–400 | 104/315 | 33.00 | 0.95 | 87 |
80–400 | 90/254 | 35.40 | 14.31 | 148 |
100–400 | 75/213 | 35.20 | 28.60 | 189 |
150–400 | 42/127 | 33.10 | 60.00 | 275 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Matusali, G.; Colavita, F.; Lapa, D.; Meschi, S.; Bordi, L.; Piselli, P.; Gagliardini, R.; Corpolongo, A.; Nicastri, E.; Antinori, A.; et al. SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses 2021, 13, 655. https://doi.org/10.3390/v13040655
Matusali G, Colavita F, Lapa D, Meschi S, Bordi L, Piselli P, Gagliardini R, Corpolongo A, Nicastri E, Antinori A, et al. SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses. 2021; 13(4):655. https://doi.org/10.3390/v13040655
Chicago/Turabian StyleMatusali, Giulia, Francesca Colavita, Daniele Lapa, Silvia Meschi, Licia Bordi, Pierluca Piselli, Roberta Gagliardini, Angela Corpolongo, Emanuele Nicastri, Andrea Antinori, and et al. 2021. "SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus" Viruses 13, no. 4: 655. https://doi.org/10.3390/v13040655